5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas

• DOI: 10.1038/srep20882
• Publication Date: 2016-02-11T10:25:56Z
• Authors: Feng Zhang; Yifan Liu; Zhiwen Zhang; Jie Li; Yi Wan; Liying Zhang; Yangmei Wang; Xia Li; Yuqiao Xu; Xin Fu; Xiumin Zhang; Ming Zhang; Zhekai Zhang; Jing Zhang; Qingguo Yan; Jing Ye; Zhe Wang; Charlie Degui Chen; Wei Lin; Qing Li
• Keywords: 5-Hydroxymethylcytosine

Abstract Currently, the reliable prognostic biomarkers for WHO grade II diffuse astrocytomas (DA) are still limited. We investigated relations between level of 5-Hydroxymethylcytosine (5hmC), an oxidated production 5-methylcytosine (5mC) by ten eleven translocated (TET) enzymes, and clinicopathological features glioma patients. With identified anti-5hmC antibody, we performed immunohistochemistry in 287 cases. detected that 5hmC variably reduced most gliomas reduction was closely associated with higher pathological grades shortened survival In multivariate analysis, had no independent value entire patient cohort. However, analysis within subtypes revealed a marker confined to DA. addition, IDH1 mutation DNA sequencing favorable Lastly, combination 5hmC/KI67 useful restratification